Literature DB >> 29031637

Molecular epidemiology of multi- and extensively-drug-resistant Mycobacterium tuberculosis in Ireland, 2001-2014.

E Roycroft1, R F O'Toole2, M M Fitzgibbon3, L Montgomery4, M O'Meara5, P Downes5, S Jackson6, J O'Donnell6, I F Laurenson7, A M McLaughlin8, J Keane8, T R Rogers3.   

Abstract

OBJECTIVES: The primary objective of this work was to examine the acquisition and spread of multi-drug resistant (MDR) tuberculosis (TB) in Ireland.
METHODS: All available Mycobacterium tuberculosis complex (MTBC) isolates (n = 42), from MDR-TB cases diagnosed in Ireland between 2001 and 2014, were analysed using phenotypic drug-susceptibility testing, Mycobacterial-Interspersed-Repetitive-Units Variable-Number Tandem-Repeat (MIRU-VNTR) genotyping, and whole-genome sequencing (WGS).
RESULTS: The lineage distribution of the MDR-TB isolates comprised 54.7% Euro-American, 33.3% East Asian, 7.2% East African Indian, and 4.8% Indo-Oceanic. A significant association was identified between the East Asian Beijing sub-lineage and the relative risk of an isolate being MDR. Over 75% of MDR-TB cases were confirmed in non-Irish born individuals and 7 MIRU-VNTR genotypes were identical to clusters in other European countries indicating cross-border spread of MDR-TB to Ireland. WGS data provided the first evidence in Ireland of in vivo microevolution of MTBC isolates from drug-susceptible to MDR, and from MDR to extensively-drug resistant (XDR). In addition, they found that the katG S315T isoniazid and rpoB S450L rifampicin resistance mutations were dominant across the different MTBC lineages.
CONCLUSIONS: Our molecular epidemiological analyses identified the spread of MDR-TB to Ireland from other jurisdictions and its potential to evolve to XDR-TB.
Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug resistance; Molecular epidemiology; Tuberculosis

Mesh:

Year:  2017        PMID: 29031637     DOI: 10.1016/j.jinf.2017.10.002

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  6 in total

1.  Comparison of two molecular diagnostic methods for identifying Beijing genotype of Mycobacterium tuberculosis.

Authors:  Ghorban Ali Mahghani; Mohammad Kargar; Farshid Kafilzadeh; Homa Davoodi; Ezzat Allah Ghaemi
Journal:  Iran J Microbiol       Date:  2020-06

Review 2.  Mycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery.

Authors:  Vaishali P Waman; Sundeep Chaitanya Vedithi; Sherine E Thomas; Bridget P Bannerman; Asma Munir; Marcin J Skwark; Sony Malhotra; Tom L Blundell
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

3.  Reporting practices for genomic epidemiology of tuberculosis: a systematic review of the literature using STROME-ID guidelines as a benchmark.

Authors:  Brianna Cheng; Marcel A Behr; Benjamin P Howden; Theodore Cohen; Robyn S Lee
Journal:  Lancet Microbe       Date:  2021-03-02

4.  Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa.

Authors:  Selien Oostvogels; Serej D Ley; Tim H Heupink; Anzaan Dippenaar; Elizabeth M Streicher; Elise De Vos; Conor J Meehan; Keertan Dheda; Rob Warren; Annelies Van Rie
Journal:  Microb Genom       Date:  2022-04

5.  Tuberculosis in Poland: Epidemiological and Molecular Analysis during the COVID-19 Pandemic.

Authors:  Dagmara Borkowska-Tatar; Anna Zabost; Monika Kozińska; Ewa Augustynowicz-Kopeć
Journal:  Diagnostics (Basel)       Date:  2022-08-03

6.  Draft Genome Sequence of an Isolate of Extensively Drug-Resistant Mycobacterium tuberculosis from Nepal.

Authors:  Sanjay S Gautam; Kelvin W C Leong; Manoj Pradhan; Y Ibotomba Singh; Sagar K Rajbhandari; Gokarna R Ghimire; Krishna Adhikari; Uma Shrestha; Raina Chaudhary; Gyanendra Ghimire; Sundar Khadka; Ronan F O'Toole
Journal:  Microbiol Resour Announc       Date:  2020-01-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.